Latest News - AMD

Wednesday, June 28, 2017 | Product Releases, AMD

MacuLogix Announces Communication Guide for Eye Care Professionals Who Diagnose and Treat AMD

MacuLogix released a step-by-step communication guide for eye care professionals treating patients with AMD. MacuLogix collaborated with Laurie Sorrenson, OD, to develop its “12 Ways to Turn an …

Read the full story

Tuesday, June 27, 2017 | Product Releases, AMD, OD-OS GmbH

OD-OS Launches Prepanned PRP for its Navilas Laser System

OD-OS announced the market release of its preplanned panretinal photocoagulation (PRP) capability for Navilas 577s. Preplanned PRP allows the physician to lay out the treatment strategy for the periph…

Read the full story

Thursday, June 22, 2017 | Clinical Trials, Retina, AMD

RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals announced the completion of enrollment in its phase 1/2 study RXI-109-1501. This multicenter, multidose, dose escalation trial is being conducted in patients with advanced neovascu…

Read the full story

Wednesday, June 21, 2017 | Medical Studies, AMD

International Academy of Low Vision Specialists Recognizes the Mental Health Changes That May Come with a Diagnosis of AMD

The diagnosis of low vision due to age, such as macular degeneration, often comes with more consequences than just the inability to see. A new study by the National Eye Institute (NEI) reports that pa…

Read the full story

Tuesday, June 20, 2017 | Clinical Trials, AMD, Novartis

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Thursday, June 15, 2017 | Medical Studies, Retina, AMD

Aflibercept May Be Effective for Resistant Exudative AMD

Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report. "…

Read the full story

Monday, February 06, 2017 | Acquisitions/Mergers, AMD

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Retinal Disease Therapy From University of Pittsburgh Medical Center

BioTime announced the acquisition of global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center (UPMC), via the school’s Innovat…

Read the full story

Friday, February 03, 2017 | Medical Studies, Retina, AMD

Dexamethasone Implant With Anti-VEGF Explored for Wet AMD

Used in combination with antivascular endothelial growth factor (anti-VEGF) therapy, dexamethasone implants (0.7 mg Ozurdex, Allergan) may help some patients with neovascular age-related macular degen…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Wednesday, February 01, 2017 | Management/Leadership, AMD, Ophthotech

Ophthotech Announces Strategic Review Plan

Ophthotech announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value. Without limiting any option, the principal focus of this plan is to activ…

Read the full story

Monday, January 30, 2017 | Product Releases, AMD, Genentech

Lucentis 0.5 mg Prefilled Syringe Now Available to Order in the US

Ophthalmologists across the United States can now order the Lucentis 0.5 mg prefilled syringe (PFS). The PFS is a new method of administering Lucentis to treat people with wet age-related macular dege…

Read the full story

Friday, January 13, 2017 | Acquisitions/Mergers, AMD, ForSight Vision

ForSight Vision 4 Announces Acquisition by Roche

ForSight Vision 4 announced that it has been acquired by Roche Holdings. The acquisition expands Roche's exclusive access to the ForSight Vision 4 PDS technology for long-acting delivery of therap…

Read the full story

Thursday, January 12, 2017 | Clinical Trials, AMD

FDA Grants "Safe to Proceed" Status to Hemera Biosciences' Gene Therapy IND Application

Hemera Biosciences has announced that the FDA has granted “safe to proceed” status to the investigational new drug application for HMR59 on December 30, 2016. A phase 1 clinical trial in p…

Read the full story

Friday, January 06, 2017 | Partnerships, AMD

Lin Bioscience Licenses First-in-Class Therapeutic Program to Treat Dry AMD from Columbia University in Collaboration with NIH

Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a first-in-class medication intended to slow …

Read the full story

Friday, January 06, 2017 | FDA Approval/Clearance, Acucela, AMD

Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease

Acucela announced that the FDA granted orphan drug designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease. The orphan drug designation doe…

Read the full story
Load More